Loading...
XIDX
KAEF
Market cap195mUSD
Nov 12, Last price  
585.00IDR
Name

Kimia Farma Tbk PT

Chart & Performance

D1W1MN
XIDX:KAEF chart
P/E
—
P/S
0.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.09%
Rev. gr., 5y
1.12%
Revenues
9.94t
-0.26%
2,704,728,409,7032,854,057,690,4793,183,829,303,9093,481,166,441,2593,734,241,101,3094,348,073,988,3854,521,024,379,7594,860,371,483,5245,811,502,656,4316,127,479,369,4037,454,114,741,1889,400,535,476,00010,006,173,023,00012,857,626,593,0009,606,145,359,0009,965,033,049,0009,938,958,364,000
Net income
-842.27b
L-43.30%
55,393,774,86962,506,876,510138,716,044,100171,765,487,458205,133,316,635214,549,154,260234,625,679,206248,849,016,194267,414,092,891326,786,249,091415,895,778,06815,890,439,00017,638,834,000302,273,634,000-94,326,886,000-1,485,563,806,000-842,272,199,000
CFO
153.62b
P
0000230,612,654,491253,783,664,733286,309,255,381202,843,123,322213,428,524,82732,637,596,011195,745,470,000-1,853,834,642,0001,018,975,185,000-223,924,978,000131,283,782,000-364,575,420,000153,616,294,000
Dividend
May 23, 202216.32735 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and sells generic, ethical, license and narcotic medicines, and over the counter medicines, health equipment, raw materials, medicines, medical devices, and cosmetics. In addition, the company distributes its products in drug to pharmacies, hospital pharmacy installation, medical center, and drug stores. The company was founded in 1817 and is headquartered in Jakarta, Indonesia.
URL
http://www.kimiafarma.co.id
IPO date
Jul 04, 2001
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT